The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Expansion Is Predicted For The Glycopeptide Antibiotics Market Between 2026 And 2030?
The glycopeptide antibiotics market size has experienced strong growth in recent years. It is projected to expand from $3.78 billion in 2025 to $4.13 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.0%. The growth observed historically can be attributed to an increase in hospital-acquired infections, the extensive use of vancomycin as a standard therapeutic approach, a rising prevalence of gram-positive bacterial infections, the limited supply of alternative antibiotics, and the expansion of inpatient healthcare infrastructure.
The glycopeptide antibiotics market size is anticipated to experience substantial expansion in the coming years. Projections indicate it will reach $5.89 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.3%. This expansion during the forecast period is primarily driven by factors such as the rise in multidrug-resistant pathogens, greater uptake of long-acting glycopeptides, increasing need for outpatient and home-based antibiotic treatments, ongoing research and development into next-generation glycopeptides, and escalating worldwide healthcare spending. Key developments expected during this period involve an increased reliance on glycopeptides for managing resistant infections, the broadening of the lipoglycopeptide antibiotics product range, greater utilization of intravenous glycopeptides in hospitals, an intensified emphasis on optimal dosing and therapeutic oversight, and broader application in severe gram-positive infections.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9444&type=smp
What Key Drivers Are Influencing The Growth Of The Glycopeptide Antibiotics Market?
The increasing incidence of gram-positive infections is projected to stimulate the expansion of the glycopeptide antibiotic market in the coming years. Gram-positive infections are caused by gram-positive bacteria such as Staphylococcus aureus, Streptococcus pneumoniae, and Streptococcus pyogenes, among others. Glycopeptide antibiotics are potent against many gram-positive bacteria due to their distinctive mechanism of action, which interferes with bacterial cell wall formation. For instance, in June 2023, the Group A Streptococcal Infections: Report on Seasonal Activity in England 2022–2023, issued by the UK Health Security Agency, a UK-based government body responsible for public health and infectious-disease protection, indicated a sharp rise in invasive Group A Streptococcus (iGAS) activity. There were 509 laboratory-confirmed iGAS notifications by week 46 of 2023, including a weekly peak of 73 cases. This escalation underscores a growing burden of infectious diseases and heightens the demand for effective antimicrobial therapies across the healthcare system. Thus, the increasing prevalence of gram-positive infections is acting as a driver for the glycopeptide antibiotic market.
Which Market Segments Are Examined In The Glycopeptide Antibiotics Market Study?
The glycopeptide antibiotics market covered in this report is segmented –
1) By Drug: Vancomycin, Dalbavancin, Oritavancin, Other Drugs
2) By Route of Administration: Oral, Parenteral, Other Routes
3) By Indication: Skin And Structure Infection, Meningitis, Clostridioides Difficile Infection, Enterocolitis, Other Indications
4) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users
Subsegments:
1) By Vancomycin: Vancomycin Injection, Vancomycin Oral Solution, Vancomycin Capsules, Vancomycin Powder for Solution
2) By Dalbavancin: Dalbavancin IV (Intravenous) Formulation, Dalbavancin Powder for Injection
3) By Oritavancin: Oritavancin IV (Intravenous) Formulation, Oritavancin Powder for Injection
4) By Other Drugs: Teicoplanin, Glycopeptide and Lipoglycopeptide Antibiotics
Which Trends Are Influencing The Glycopeptide Antibiotics Market?
Key players within the glycopeptide antibiotics market are prioritizing the creation of innovative products, such as novel glycopeptide scaffolds, to achieve a competitive advantage. These new glycopeptide scaffolds are structurally unique antibiotic backbones, originating from advanced biosynthetic or natural-product discovery methods. For example, in May 2025, a Chinese-European research consortium, described as a China-based cross-continental expertise, unveiled Saarvienin A. This recently identified glycopeptide possesses a halogenated peptide core, an uncommon ureido linkage, and five distinct sugar or aminosugar components. Saarvienin A does not engage with the traditional cell-wall target of other glycopeptides, suggesting a potentially new mechanism of action, and displays strong in vitro activity against resistant Gram-positive pathogens like MRSA and vancomycin-resistant Enterococcus. While this development represents a significant stride in addressing antibiotic resistance, it encounters challenges including its clinical application, optimization for safety, and scaling up production.
Who Are The Primary Competitors In The Glycopeptide Antibiotics Market?
Major companies operating in the glycopeptide antibiotics market are ANI Pharmaceuticals Inc., Fresenius SE & Co. KGaA, Pfizer Inc., Novartis AG, Hikma Pharmaceuticals Plc., Aurobindo Pharma Limited, Abbvie Inc., Cumberland Pharmaceuticals Inc., Janssen Global, Bristol-Myers Squibb Company, Shenwei Pharmaceutical Hainan Co. Ltd., Zhejiang Hisun Pharmaceutical Co. Ltd., Alvogen, Bayer AG, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Sanofi SA, GlaxoSmithKline plc, Johnson & Johnson, AstraZeneca, Boehringer Ingelheim GmbH, Cipla Inc.
Read the full glycopeptide antibiotics market report here:
https://www.thebusinessresearchcompany.com/report/glycopeptide-antibiotics-global-market-report
Which Region Is Expected To Register The Fastest Growth In The Glycopeptide Antibiotics Market?
North America was the largest region in the glycopeptide antibiotics market in 2025. The regions covered in the glycopeptide antibiotics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Glycopeptide Antibiotics Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=9444&type=smp
Browse Through More Reports Similar to the Global Glycopeptide Antibiotics Market 2026, By The Business Research Company
Glycopeptide Antibiotics Market Report 2026
https://www.thebusinessresearchcompany.com/report/glycopeptide-antibiotics-global-market-report
Peptide Antibiotics Market Report 2026
https://www.thebusinessresearchcompany.com/report/peptide-antibiotics-global-market-report
Antibiotics Market Report 2026
https://www.thebusinessresearchcompany.com/report/antibiotics-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model